Sulfonylurea-induced decrease of muscle capillary basement membrane thickness in diabetes.
Three muscle biopsies were performed in 53 overt type 2 diabetics over a period of approximately 2 years. At baseline, 21 (40%) had an increased capillary basement membrane width in muscle. Thirty-five patients received glipizide and 18 received placebo. In the patients receiving placebo, the mean of the muscle capillary basement membrane width increased from 158.7 +/- 11.5 nm (SEM) to 170.9 +/- 14.7 nm (P = NS), but in those receiving glipizide the value decreased from 192.9 +/- 13.2 nm to 161.0 +/- 10.2 nm (P = 0.02). Plasma glucose and glycosylated hemoglobin A1 decreased significantly (P less than 0.001) after 2 years in patients receiving glipizide. In 15, mean glycosylated hemoglobin A1 reached a normal range, and mean basement membrane width decreased to a level close to that found in subjects without diabetes (P = NS). These findings are consistent with the hypothesis that effective response to oral medication can decrease the basement membrane thickening, suggesting that diabetic microangiopathy is not necessarily progressive.
D000328:Adult; D001485:Basement Membrane / Q000187:drug effects / Q000648:ultrastructure*; D001786:Blood Glucose / Q000032:analysis; D002196:Capillaries / Q000187:drug effects / Q000648:ultrastructure*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D005500:Follow-Up Studies; D005913:Glipizide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008875:Middle Aged; D009132:Muscles / Q000098:blood supply* / Q000648:ultrastructure; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D001786:Blood Glucose; D005913:Glipizide; D006442:Glycated Hemoglobin; D013453:Sulfonylurea Compounds